Drug Database · Clinicians

Baclofen

Brands (10) Liosal, Bac-10, Baclisolv…Show all

gamma-Aminobutyric Acid-ergic Agonist (GABA A Agonists; GABA B Agonists) US FDA class
Muscle relaxant (centrally acting agent) PH FDA category

Rx · Prescription drug12 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c17527be-661d-42f5-b6f6-56a681ba7870, version date August 24, 2026 (Baclofen · Par Health USA, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Baclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Baclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function.

Baclofen tablets USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen tablets USP are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions.

Contraindications

CONTRAINDICATIONS Hypersensitivity to baclofen.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40 to 80 mg daily). The following dosage titration schedule is suggested: 5 mg t.i.d. for 3 days 10 mg t.i.d. for 3 days 15 mg t.i.d. for 3 days 20 mg t.i.d. for 3 days Thereafter additional increases may be necessary but the total daily dose should not exceed a maximum of 80 mg daily (20 mg q.i.d.).

The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a reasonable trial period, patients should be slowly withdrawn from the drug (see WARNINGS, Abrupt Drug Withdrawal).

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Tablet: 10 mg
  • Film-coated tablet: 10 mg

Registered products in the Philippines

12 products registered with the Food and Drug Administration (FDA) Philippines list Baclofen as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products12
Philippine FDA-registered products for Baclofen
Package insert
Bac-10Baclofen
10 mg TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's
Rx
Hizon Laboratories, Inc.Philippines
Sigma Medical Solution Trading Co. Inc.
DRP-4052
Aug 13, 2027
BaclisolvBaclofen
10 mg TabletAlu/PVC Blister Pack x 10’s (Box of 50’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Premier Pharmaceuticals Marketing Corp.Importer: Ambica International Corporation
DRP-10598
Oct 22, 2031
BaclorBaclofen
10 mg TabletAlu/PVDC Blister Pack x 10’s (Box of 30’s and 50’s)
Rx
Eskayef Pharmaceuticals LimitedBangladesh
Ambica International CorporationImporter: Ambicare Pharmaceuticals, Inc.
DRP-10509-01
Oct 8, 2031
Baxan 10Baclofen
10 mg TabletAlu/PVC Blister Pack x 10's
Rx
Globela Pharma Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-18679
Dec 8, 2031
FenobacBaclofen
10 mg TabletAlu/PVDC Blister Pack x 10's (Box of 30's and 50's)
Rx
Eskayef Pharmaceuticals LimitedBangladesh
Ambicare Pharmaceuticals Inc.
DRP-10509
Oct 8, 2031
LioresalBaclofen
10 mg TabletBlister Pack x 10's (Box of 50's)
Rx
Novartis Farma S.p.AItaly
Novartis Healthcare Philippines, Inc.
DR-X8065
Sep 3, 2029
LiosalBaclofen
10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10 's (Box of 20's and 100's)
Rx
DELTA PHARMA LTD.Bangladesh
BIOMED PHARMA INC.
DR-XY40693
Feb 25, 2030
LiosalBaclofen
10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's and 100's)
Rx
Delta Pharma Ltd.Bangladesh
Biomed Pharma Inc.
DRP-17367
Feb 25, 2030
MyafenBaclofen
10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's and 100's)
Rx
Delta Pharma Ltd.Bangladesh
The Cathay Yss Distributors Co., IncImporter: Biomed Pharma Inc.
DRP-17367-01
Feb 25, 2030
SpilogenBaclofen
10mg TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Celogen Generics Private Ltd.India
Saifen Drugs Philippines, Inc.
DR-XY49342
Feb 25, 2030
TrilaxantBaclofen
10 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
Yooyoung Pharmaceutical Co., Ltd.Republic of Korea
One Pharma Marketing Inc.Importer: H & B Pharma International Inc.
DR-XY35815
May 13, 2029
(no brand name)Baclofen
10 mg TabletAlu/PVdC Blister Pack x 10's (Box of 100's)
Rx
Eskayef Pharmaceuticals limitedBangladesh
One Pharma Marketing, Inc.Importer: Brightwell Marketing and Distributions Inc.
DRP-18452
Jul 14, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure. If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradually reduce the dose and discontinue baclofen before delivery.

If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen. Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued.

Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. Stroke: Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerability to the drug. Pregnancy: Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams.

This abnormality was not seen in mice or rabbits. There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose.

In mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose. There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%).

Others reported: Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular: Hypotension (0 to 9%).

Rare instances of dyspnea, palpitation, chest pain, syncope. Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria.

Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion. Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY The precise mechanism of action of baclofen is not fully known. Baclofen is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect.

Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects. In studies with animals baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression.

Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses. Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Baclofen 10 mg Tablet₱10.98–₱15.50Reference ₱13.80per tabletDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Baclofen
PNF listingOral: 10 mg tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Baclofen · Par Health USA, LLC [US FDA-approved label, version 24, August 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c17527be-661d-42f5-b6f6-56a681ba7870
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .